The long-term safety of adalimumab treatment in moderate to severe psoriasis: A comprehensive analysis of all adalimumab exposure in all clinical trials

American Journal of Clinical Dermatology

Volumn 12, Issue 5, 2011, Pages 321-337

  Leonardi, Craig ^a   Papp, Kim ^b   Strober, Bruce ^c   Reich, Kristian ^d   Asahina, Akihiko ^e   Gu, Yihua ^f   Beason, Joseph ^f   Rozzo, Stephen ^f   Tyring, Stephen ^g  

^a Central Dermatology   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DERMATOLOGIKUM HAMBURG   (Germany)

^e SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^f ABBOTT LABORATORIES   (United States)

^g University of Texas Health Science Center at Houston   (United States)

Author keywords

Adalimumab; Psoriasis; Tumour necrosis factor alpha inhibitors

Indexed keywords

ADALIMUMAB;

ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; CELLULITIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; DEMYELINATING DISEASE; DISEASE DURATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; LONG TERM EXPOSURE; LUNG EDEMA; LUPUS LIKE SYNDROME; LUPUS VULGARIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OPPORTUNISTIC INFECTION; OROPHARYNX CANDIDIASIS; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; RHINOPHARYNGITIS; RISK ASSESSMENT; STROKE; SWELLING; THRUSH; TONGUE SWELLING; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 80051736594     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11587890-000000000-00000     Document Type: Article

References (27)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. New Engl J Med 1995; 332: 581-8
2. Thaci D. Long-term data in the treatment of psoriasis. Br JDermatol 2008; 159 Suppl. 2: 18-24
3. Winterfield LS, Menter A, Gordon K, et al. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005; 64 Suppl. 2: ii87-90; discussion ii1-2 (Pubitemid 40288531)
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-85
5. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-9
6. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64 (6): 1035-50
7. Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310
8. Gordon KB, Blum RR, Papp KA, et al. Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial. Psoriasis Forum 2007; 13: 6-11
9. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606 (Pubitemid 44436647)
10. Larian A, Emer JJ, Gordon K, et al. Efficacy and safety of a second adalimumab treatment cycle in psoriasis patients who relapsed after adalimumab discontinuation or dosage reduction: a double-blind, randomized, placebocontrolled trial. Psoriasis Forum. In press
11. Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147: 429-36
12. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15 (Pubitemid 350298146)
13. Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br JDermatol 2011; 164: 434-41
14. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66 (Pubitemid 351239154)
15. Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol 2011; 64: 671-81
16. Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-11
17. World Health Organization. Mortality database [online]. Available from URL: http://www.who.int/whosis/database/mort/table1.cfm [Accessed 2010 Jul 26]
18. Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arth Rheum 2008; 58: 3299-308
19. Demers AA, Nugent Z, Mihalcioiu C, et al. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol 2005; 53: 320-8 (Pubitemid 40979591)
20. Ridky TW. Nonmelanoma skin cancer. J AmAcad Dermatol 2007; 57: 484-501 (Pubitemid 47239135)
21. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-6
22. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-3
23. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-92
24. Kimball AB, Guerin A, Latremouille-Viau D, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 2010; 123: 350-7
25. Leonardi C, Papp K, Asahina A, et al. Long-term safety of adalimumab for psoriasis: an analysis of all adalimumab exposure in all global clinical trials [abstract no. P3337]. Presented at the 68th Annual Meeting of the American Academy of Dermatology; 2010 Mar 5-9; Miami Beach (FL)
26. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55 (Pubitemid 36278124)
27. Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010; 162: 1349-58